RA Capital
About RA Capital
RA Capital Management funds and builds healthcare and life science companies, with a growing interest in climate and sustainability technologies. It operates as a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm emphasizes data-driven insights and deep domain expertise to support portfolio companies across the biotechnology and healthcare spectrum, including venture and growth stages. Headquartered in the United States, RA Capital engages in venture activity and internal research initiatives such as TechAtlas to analyze scientific and clinical data relevant to biotech and healthcare investing.
Recent News
Sydnexis to Present New Data From Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
The IPO Buzz: Hemab Therapeutics (COAG) Prices Upsized IPO at $18 – Top – & Stock Pops
Syneron Raises $150m for Macrocyclics, and Other Financings
April 7 Business Watch: Iran War Hits Persian Gulf Facilities; Trump Throws Tariffs on Pharma
Karyopharm’s Mixed Myelofibrosis Data; Rezolute to Seek FDA Approval Despite Trial Failure
Recent Deals
RA Capital Planetary Health Closes $120M Fund
Azalea Therapeutics Secures $82M in Series A Funding Led by Third Rock Ventures
VitriVax Raises $17.25M Series B to Advance Thermostable Vaccine Technology
Parabilis Medicines Secures $305M Series F Funding Led by RA Capital, Fidelity Management, and Janus Henderson
Triana Biomedicines Secures $120M Series B Funding Led by Ascenta Capital and Bessemer
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Slate Medicines Secures $130M Series A Funding Led by RA Capital, Forbion and Foresite Capital
Corxel Secures $287M Series D1 Funding to Advance Oral GLP-1 Obesity Pill
Avalanche Energy Raises $29M in New Funding Led by RA Capital Management
VitriVax Raises $17.25M Series B Led by Adjuvant Capital and RA Capital
Hemab Therapeutics Raises $157M in Series C Led by Sofinnova Partners